Cystic Fibrosis: NovaBiotics Advances Old Dog With New Tricks
Lynovex, a reformulated version of a molecule which has been around for decades for a rare metabolic disease, has just succeeded in a Phase IIb study to treat exacerbations in cystic fibrosis. The mutation-agnostic therapy could improve on current treatments for breakthrough exacerbations, and reduce the associated long-term damaged.
You may also be interested in...
The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.